Comparing two HIV medication regimens in people with controlled virus

This trial is testing whether a newer two-drug HIV regimen called Dovato (dolutegravir and lamivudine) works as well as a standard three-drug regimen in people whose HIV is already well-controlled. Researchers want to understand how the medication affects both viral control and immune health, and whether it causes fewer side effects than the three-drug option.

Newer two-drug HIV regimens may offer benefits like fewer pills, fewer side effects, and lower cost compared to traditional three-drug combinations—but researchers need more detailed information to confirm that the medication is equally safe and effective in the long term.